XML 53 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Cash flows from operating activities:        
Net income $ 79,000 $ 96,040 $ 164,386 $ 183,491
Adjustments to reconcile net income to net cash flows from operating activities:        
Depreciation and amortization 7,040 6,724 13,882 13,482
Provision for doubtful accounts 17,487 23,034 30,154 45,799
Deferred income taxes (4,492) (6,485) (7,177) (9,463)
Excess tax benefit from stock option exercises (627) (1,019) (978) (1,940)
Stock-based compensation expense 4,758 4,186 8,672 8,999
Other (987) 334 (2,417) 490
Changes in operating assets and liabilities:        
Restricted cash 1,433 5,228 (132) 1,821
Accounts receivable (4,730) (33,134) (8,258) (58,763)
Accounts payable (6,681) 7,642 (1,912) 14,841
Other operating assets and liabilities (32,886) (20,711) 24,036 22,340
Deferred revenue 1,307 5,312 22,485 25,174
Net cash flows from operating activities 60,622 87,151 242,741 246,271
Cash flows from investing activities:        
Facility expenditures and land purchases (1,173) (1,754) (1,675) (2,593)
Capital expenditures, net (7,487) (7,241) (12,186) (12,539)
Proceeds from sales and maturities of investments and repayment of notes 118,307 115,128 260,392 199,826
Purchase of investments and note advances (123,104) (115,602) (281,693) (222,774)
Net cash flows from investing activities (13,457) (9,469) (35,162) (38,080)
Cash flows from financing activities:        
Excess tax benefit from stock option exercises 627 1,019 978 1,940
Proceeds from exercise of stock options 1,955 1,594 4,983 2,620
Repurchase of common stock and shares tendered for taxes (79,434) (105,315) (219,084) (201,015)
Net cash flows from financing activities (76,852) (102,702) (213,123) (196,455)
Net change in cash and cash equivalents (29,687) (25,020) (5,544) 11,736
Cash and cash equivalents at beginning of period 187,922 165,544 163,779 128,788
Cash and cash equivalents at end of period $ 158,235 $ 140,524 $ 158,235 $ 140,524